🔬 Educational Information: DSIP (Delta Sleep-Inducing Peptide)

Delta Sleep-Inducing Peptide (DSIP) is a synthetic nonapeptide that has been studied in research for its potential effects on sleep regulation, stress response, and hormonal balance. While its effectiveness and safety for human use have not been evaluated by the FDA, preliminary studies in animal models and isolated systems have shown potential benefits. The following dosage schedule is based on research findings and may represent possible future applications pending clinical trials and regulatory approval.

*Administered subcutaneously 30 to 60 minutes before sleep

Important Notes:

• Dosage Variability: Research on DSIP is still in early stages, and the optimal dosage for human application is not yet established.
• Start Low: Researchers often begin with 100 mcg to assess individual or animal response.
• Research Use Only: This peptide is intended for in-vitro (test tube) and ex-vivo (outside of living organisms) experiments only.
• Regulatory Approval Pending: DSIP and similar peptides have not been approved for clinical use in humans. Future potential use in clinical settings will require FDA approval after thorough testing.